Skip to content
Business Times – Lifestyle
Author:
Crescent Biopharma, Inc.
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
October 15, 2026
Crescent Biopharma Announces Grants of Inducement Awards
October 6, 2026
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
October 5, 2026
Crescent Biopharma Announces Grants of Inducement Awards
September 25, 2026
Crescent Biopharma Announces Grants of Inducement Awards
September 9, 2026
Crescent Biopharma to Present at September Investor Conferences
September 3, 2026
Crescent Biopharma Announces Grants of Inducement Awards
August 3, 2026
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
July 30, 2026
Crescent Biopharma Announces Grants of Inducement Awards
July 23, 2026
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 16, 2026
1
2
3
Next Page
→